Elite in Hereditary Angioedema

Emel Pursun-Aygoren

Frankfurt Am Main, HE, DE 
Elite in Hereditary Angioedema
Frankfurt Am Main, HE, DE 
OverviewLocationsClinical Research

Overview

Emel Pursun-Aygoren practices in Frankfurt Am Main, Germany. Pursun-Aygoren is rated as an Elite expert by MediFind in the treatment of Hereditary Angioedema. Their top areas of expertise are Angioedema, Hereditary Angioedema, Hives, and Asthma.

Their clinical research consists of co-authoring 67 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 59 articles and participated in 6 clinical trials in the study of Hereditary Angioedema.

Locations

Frankfurt Am Main, HE, Germany
Other Locations
Berlin And The Department Of Otorhinolaryngology And Head And Neck Surgery, Ulm, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Three-year, Non-interventional, Prospective, Multicenter Study to Evaluate the Long- Term Effectiveness of Lanadelumab in Real-world Clinical Practice (ENABLE)
A Three-year, Non-interventional, Prospective, Multicenter Study to Evaluate the Long- Term Effectiveness of Lanadelumab in Real-world Clinical Practice (ENABLE)
Enrollment Status: Completed
Publish Date: September 02, 2025
Icatibant Outcome Survey (IOS) Registry
Icatibant Outcome Survey (IOS) Registry
Enrollment Status: Completed
Publish Date: October 28, 2024
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: No_longer_available
Publish Date: July 24, 2023
Intervention Type: Drug
Retrospective, Observational Chart Review Study Evaluating Clinical Effectiveness and Disease/Treatment Management Among Patients Who Initiated Long-term Prophylaxis With Takhzyro® in a Real-world Setting
Retrospective, Observational Chart Review Study Evaluating Clinical Effectiveness and Disease/Treatment Management Among Patients Who Initiated Long-term Prophylaxis With Takhzyro® in a Real-world Setting
Enrollment Status: Completed
Publish Date: January 13, 2023
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
Enrollment Status: Completed
Publish Date: May 26, 2022
Intervention Type: Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
Hereditary Angioedema Kininogen Assay: A Multicenter, Epidemiological, Observational Study.
Hereditary Angioedema Kininogen Assay: A Multicenter, Epidemiological, Observational Study.
Enrollment Status: Terminated
Publish Date: March 10, 2022
View 6 Less Clinical Trials

67 Total Publications

Effectiveness and safety of Lanadelumab according to disease activity: pooled analysis of EMPOWER/ENABLE
Effectiveness and safety of Lanadelumab according to disease activity: pooled analysis of EMPOWER/ENABLE
Journal: Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)
Published: October 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Pursun-Aygoren's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile